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Background: Streptococcus pneumoniae, which cause noninvasive pneumococcal diseases,
severely impair children’s health. This study analyzed serotype distribution and antimicro-
bial  resistance of S. pneumoniae from January 2012 to December 2012 in a Children’s Hospital,
Shanghai.
Methods: A total of 328 pneumococcal isolates were serotyped by multiplex sequential PCR
and/or capsule-quellung reaction. The minimum inhibitory concentrations for 11 antimi-
crobial agents were determined by broth microdilution method.
Results: Among 328 strains, 19F (36.3%), 19A (13.4%), 6A (11.9%), 23F (11.0%), 14 (5.8%), 6B
(5.2%), and 15B/C (4.3%) were the most common serotypes. The coverage rates of 7-, 10-,
and 13-valent conjugate vaccines (PCV7, PCV10, and PCV13) were 58.2%, 58.2%, and 84.1%,
respectively. Out of the isolates, 26 (7.9%) strains were penicillin resistant. Most of the strains
displayed high resistance rate to macrolides (98.5% to erythromycin, 97.9% to azithromycin,
and  97.0% to clindamycin).
Conclusions: The potential coverage of PCV13 is higher than PCV7 and PCV10 because ofthe  emergence of 19A and there should be long-term and systematic surveillance for non-
vaccine serotypes.
© 2015 Elsevier Editora Ltda. All rights reserved.
the World Health Organization (WHO), 50–60% of the 1.6 mil-ntroductiontreptococcus pneumoniae remains a major pathogen of pneu-
onia, meningitis and acute otitis in children, with high
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.morbidity and mortality. According to a survey conducted bys Hospital of Shanghai, Shanghai Jiaotong University, No. 24, Lane
lion deaths caused by pneumococcal infections in 2005 were in
children younger than ﬁve years old, especially in developing
countries.1
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years, 6.1%). Upper respiratory tract infections were diagnosed
in 243 children (74.1%) and 35 (10.7%) had a history of contact142  b r a z j i n f e c t d 
Heptavalent pneumococcal conjugate vaccine (PCV7), tar-
geting seven of more  than 90 serotypes of S. pneumoniae
(serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), has reduced the burden
of invasive pneumococcal diseases (IPD) and nasopharyn-
geal carriage rate of these serotypes in vaccinated children in
developed countries.2,3 Moreover, several reports indicate that
in some countries PCV7 is also effective against noninvasive
pneumococcal disease (NIPD) like pneumonia.4,5 In USA, Gri-
jalva et al.4 reported that the all-cause pneumonia admission
rates had declined by 39% for children younger than two years
following licensure of PCV7. However, after the introduction of
PCV7 the incidence of pneumococcal diseases caused by non-
PCV7 serotypes such as 6A and 19A increased.6,7 The Food and
Drug Administration (FDA) approved two more  vaccines: the
10-valent pneumococcal conjugate vaccine (PCV10) including
serotypes 1, 5, and 7F in addition to PCV7 serotypes and the
13-valent pneumococcal conjugate vaccine (PCV13) including
serotypes 3, 6A and 19A in addition to PCV10 serotypes. Both
proved to be more  effective than PCV7.8–9
In Mainland China, PCV7 has not yet been introduced into
childhood immunization program despite being available in
the market since 2008. Information about the use of PCV10
and PCV13 in Mainland China has also been unclear. It has
been proposed that the choice of S. pneumoniae vaccine should
be based on the distribution of serotypes, which vary with age,
geographic region and time.10 Therefore, systematic and accu-
rate assessment of the serotype distribution of S. pneumoniae
is necessary for choosing an optimal vaccine.
Interestingly, NIPD accounts for a major proportion of all
pneumococcal infections. O’Brien et al.11 reported that out of
14.5 million pneumococcal cases, 95.6% were cases of NIPD
while only 4.4% were IPD. However, data about S. pneumoniae
isolated from children with NIPD is rare. Moreover, continued
surveillance of the distribution of pneumococcal serogroup
isolated from specimens of non-sterile sites may help deter-
mining which serogroups are important in the development
of invasive disease.5 In this study, we investigated S. pneumo-
niae isolated from children with NIPD in 2012. The purpose
of this surveillance study was to determine the serotype
distribution and antimicrobial resistance pattern of S. pneu-
moniae strains causing NIPD in Shanghai, a metropolitan city
located in the east of China. Such information could provide
guidance for further clinical and epidemiologic studies, ratio-
nal administration of antimicrobial agents, and selection of
proper vaccines.
Material  and  methods
Study  design  and  data  collection
This surveillance was conducted between January 2012 and
December 2012 in Shanghai Children’s Hospital, which is one
of the largest pediatric hospitals in Shanghai. The hospital
serves 1.13 million outpatients and 20,000 inpatient admis-
sions annually. All specimens were collected from children
(0–14 years of age) who were hospitalized and diagnosed
with NIPD. NIPD was deﬁned as S. pneumoniae strains caus-
ing infection detected in ear, eye, nasopharynx, or tracheal
aspirate specimens and in which no invasive (sterile sites) 1 5;1  9(2):141–145
isolates were collected from the same patient.12 Furthermore,
the clinical data of enrolled patients including demograph-
ics, admission and/or discharge diagnosis, time of sampling,
recent use of antimicrobial agents, vaccination history were
obtained from the medical records. If two isolates expressing
the same serotype from the same patient, only one isolate was
included with duplicates being discarded.
Clinical  isolates  and  microbiological  tests
All specimens were processed in a microbiology labora-
tory according to the “National Guide to Clinical Laboratory
Procedures”.13 A total of 328 non-duplicated strains were
included. The samples were sent to the microbiology labo-
ratory and inoculated on 5% sheep blood agar plates. The
plates were incubated at 37 ◦C in a 5% CO2 incubator and
examined after 24–48 h. Typical colonies of S. pneumoniae were
subcultured and identiﬁed by using the optochin disk (Oxoid,
Hampshire, UK) and bile solubility test.14 All strains were
stored at −80 ◦C in 40% glycerol broth medium until further
analysis. Pneumococcal isolates were serotyped by multiplex
sequential PCR15 and/or capsule-quellung reaction16 with a
set of antisera from the Statens Serum Institute (Copenhagen,
Denmark). The minimum inhibitory concentrations (MICs)
for penicillin (PEN), cefuroxime (CXM), ceftriaxone (CRO),
erythromycin (ERY), azithromycin (AZM), clindamycin (CLI),
levoﬂoxacin (LEV), moxiﬂoxacin (MXF), vancomycin (VAN) and
trimethoprim-sulfamethoxazole (SXT) were determined by
broth microdilution method according to the 2013 guidelines
of the Clinical and Laboratory Standards Institute (CLSI M100-
S23). S. pneumoniae ATCC 49619 was used as the control strain
for the susceptibility test.
Statistical  analysis
Whonet 5.6 software17 and SPSS 16.0 (Statistical Package for
Social Science, USA) were used for susceptibility statistics and
analysis. The 2 test or Fisher’s exact test of program were used
for comparing categorical data. Two-tailed p-values <0.05 were
considered statistically signiﬁcant.
Results
Demographic  data  of  patients
A total of 328 isolates of S. pneumoniae were included being
61.3% (201/328) detected in male patients and 38.7% (127/328)
in females. Patients aged between 0 and 14 years old were
divided into four groups: infant (<1 year, 37.8%), toddler (1–2
years, 28.4%), preschooler (3–5 years, 27.7%) and schooler (6–14with other infected patients. All of these patients had history
of prior hospitalization or recent physician visit and therapy
with antibiotics. Only four children (1.2%) had received PCV-7
vaccination.
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Fig. 1 – Serotype distribution and vaccine coverage of S.
pneumoniae in 2012. *NVT: non-vaccine serotypes not
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1), 11A (1), 7C (1), 17F (1); NT: nontypable isolates.
erotype  distribution
ut of 328 pneumococcal isolates, 300 strains (91.5%) were
uccessfully typed with 14 serotypes by multiplex PCR and
apsule-quellung reaction. Serotype 19F was the predomi-
ant serotype (36.3%), followed by 19A (13.4%), 6A (11.9%),
3F (11.0%), 14 (5.8%), 6B (5.2%), 15B/C (4.3%). Another eight
erotypes were detected in fewer than ﬁve strains, which
ncluded serotype 15A (4), 3 (2), 35B (2), 10A (1), 11A (1), 7C
1), 17F (1). The coverage rates of PCV7, PCV10, and PCV13
erotypes were 58.2%, 58.2% and 84.1%, respectively (Fig. 1).
ntimicrobial  susceptibility
ccording to CLSI 2013 breakpoints for parenteral peni-
illin (resistant ≥8 g/mL and intermediate 4 g/mL for
on-meningitis isolates), the prevalence rate of penicillin non-
usceptible S. pneumoniae (PNSP) was 28.6%, including 20.7%
enicillin intermediate S. pneumoniae (PISP) and 7.9% peni-
illin resistance S. pneumoniae (PRSP). Resistance to cefuroxime
as seen in 82.6% of isolates whereas 33.5% was resistant to
eftriaxone. Most of the strains displayed high resistance rate
Table 1 – Antimicrobial resistance rates of 328 S. pneumoniae iso
agents.
PEN
No. (%)
CXM
No.  (%)
CRO
No.  (%)
ERY
No.  (%)
AZM
No.  (%
19F 12 (12.1) 112 (94.1) 74 (62.2) 118 (99.2) 118 (99
19A 0 (0) 43 (97.7) 3 (6.8) 43 (97.7) 43 (97
6A 0 (0) 24 (61.5) 3 (7.7) 39 (100) 38 (97
23F 1 (2.8) 29 (80.6) 2 (5.6) 36 (100) 36 (10
14 0 (0) 14 (73.7) 6 (31.6) 19 (100) 19 (10
6B 0 (0) 12 (70.6) 3 (17.6) 16 (94.1) 16 (94
3 0 (0) 0 (0) 2 (100) 2 (100) 2 (10
NVT 2 (8.3) 18 (75.0) 2 (8.3) 23 (95.8) 22 (91
NT 11 (39.3) 19 (67.9) 15 (53.6) 27 (96.4) 27 (96
Total 26 (7.9) 271 (82.6) 110 (33.5) 323 (98.5) 321 (97
PEN, penicillin; CXM, cefuroxime; CRO, ceftriaxone; ERY, erythromycin; A
ﬂoxacin; VAN, vancomycin; SXT; trimethoprim-sulfamethoxazole.5;1 9(2):141–145 143
to macrolides (98.5% to erythromycin, 97.9% to azithromycin)
and to clindamycin (97.0%).
In sharp contrast, all of these isolates were susceptible to
levoﬂoxacin, moxiﬂoxacin and vancomycin with the excep-
tion of one strain (0.3%) that was resistant to levoﬂoxacin and
intermediate to moxiﬂoxacin. In addition, the resistance rate
to trimethoprim-sulfamethoxazole was 75.3%.
Association  between  antimicrobial
susceptibility  and  serotype
We  further assessed antimicrobial susceptibility of S. pneu-
moniae among different serotypes (Table 1). Serotype 19F
showed the highest resistance rate to penicillin, ceftriaxone
and trimethoprim-sulfamethoxazole. The highest prevalence
of cefuroxime resistance was observed with serotype 19A. All
of 14 serotypes exhibited high resistance rates to macrolides
and clindamycin.
Furthermore, among antimicrobial non-susceptible iso-
lates including -lactamase, macrolides and sulfonamides,
the coverage rates of PCV7 types were signiﬁcantly higher
than non-PCV7 types (p < 0.05). The common serotypes in PNSP
were 19F and 19A, accounting for 68.1% and 10.6%, respec-
tively.
Discussions
Pneumococcal conjugate vaccine, development of which is
based on the local serotype distribution, is one of the
important measures to prevent invasive and noninvasive
infections by S. pneumoniae and also prevent the spread of drug
resistance.1 Owing to capsular polysaccharide, S. pneumoniae
can be differentiated into 90 distinct serotypes but only a few
can cause serious diseases.18
PCV7, ﬁrstly introduced in 2000 in USA, was recom-
mended as a part of routine childhood immunization by
the WHO  in 2007. However, after wide application of PCV7,
“serotype replacement”, a phenomenon that PCV7 serotypes
decreased with concurrent increase of NVTs among invasive
and noninvasive diseases was observed.6 Similarly, this study
lates of different serotypes against 10 antimicrobial
)
CLI
No. (%)
LEV
No.  (%)
MXF
No. (%)
VAN
No.  (%)
SXT
No. (%)
.2) 117 (98.3) 0 (0) 0 (0) 0 (0) 111 (93.3)
.7) 43 (97.7) 0 (0) 0 (0) 0 (0) 40 (90.9)
.4) 38 (97.4) 0 (0) 0 (0) 0 (0) 18 (46.2)
0) 36 (100) 0 (0) 0 (0) 0 (0) 25 (69.4%)
0) 19 (100) 0 (0) 0 (0) 0 (0) 3 (15.8)
.1) 14 (82.4) 0 (0) 0 (0) 0 (0) 13 (76.5)
0) 2 (100) 0 (0) 0 (0) 0 (0) 0 (0)
.7) 22 (91.7) 0 (0) 0 (0) 0 (0) 13 (54.2)
.4) 27 (96.4) 1 (3.6) 0 (0) 0 (0) 24 (85.7)
.9) 318 (97.0) 1 (0.3) 0 (0) 0 (0) 247 (75.3)
ZM, azithromycin; CLI, clindamycin; LEV, levoﬂoxacin; MXF, moxi-
i s . 2 0
r
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demonstrated that 19F, 19A, 6A and 23F were the most fre-
quent serotypes, as had been observed in another study
conducted by Yao et al. in Mainland China.19 Out of the most
common serotypes, 19A and 6A are non-PCV7 serotypes and
represented 25.3% of all isolates. As reported by Hackel et al.,20
19A became the most common serotype in children less than
ﬁve years after introduction of PCV7 throughout the world.
In the United States, the prevailing serotypes causing NIPD
between 1999–2011 were 19A, 3 and 35B, which increased
from 2% to 22%, 8.5% to 9.3%, 4.0% to 7.0%, respectively.21
A review shows that in Europe the most common isolates
were serotypes 1, 19A, 3, 6A, and 7F after PCV7 introduction
in Belgium, France, Germany, Greece, Norway, Portugal, Spain,
and the UK.22 Therefore, there should be long-term and sys-
tematic surveillance for non-vaccine serotypes, especially 19A
serotype.
In addition, the coverage rates of PCV7 also changed
under the same condition. In Europe, vaccine serotype cov-
erage rate ranged from 37% to 100% for PCV7, with mean
increases in coverage of 7% and 16% for PCV10 and PCV13,
respectively.22 Furthermore, in Hong Kong, the proportion
of PCV7 serotypes on IPD declined from 89.5% to 65.7%
but that of PCV13 remained stable (91.4–93.2%).23 A Chinese
multicenter study on NIPD of children19 showed that PCV7,
PCV10, and PCV13 covered 76.3%, 76.9%, and 92.3% of iso-
lates, respectively. However, our study suggested that the
coverage rates of PCV7, PCV10, and PCV13 were 58.2%, 58.2%,
and 84.1%, respectively, lower than other studies,24,25 which
may be the result of increasing non-PCV types in Mainland
China.
Antimicrobial agents, especially penicillin, are always used
for treating pneumococcal infections. However, since the PRSP
isolates were ﬁrst discovered in Australia, the phenomenon
of S. pneumoniae antimicrobial resistance has posed a major
challenge. In the United States, resistance rates for penicillin
increased from 5.3% to 15.9% from 2004 to 2009.26 The propor-
tions of PNSP throughout Europe was 0.4% in Belgium, 3.1%
in UK, 3.7% in Germany, 9.2% in Italy, 15% in Hungary, and
27.6% in France.27 Among Asian countries, the PNSP rate was
13.2% in China, 1.5% in Hong Kong, and 2.2% in South Korea.28
Despite the decline of non-susceptibility rate with the revision
of the new CLSI breakpoints in developed countries, the rate
of PNSP in China remained high.19,29
At present, it is remarkable the relationship between peni-
cillin resistance and serotypes. In Japan, signiﬁcantly higher
rates of penicillin resistant isolates were mostly found in 19F
and 23F serotypes.30 Half of the penicillin resistant isolates
were identiﬁed as serotype 19F in China.19 However, some
surveys in western countries have reported that non-PCV7
serotypes, 19A in particular, have become not only more  preva-
lent, but also more  resistant to antimicrobials. In the United
States21 most PRSP isolates were serotypes 19A (75.3%), 35B
(11.1%), or 19F (7.2%). Moreover, we detected that 19A was also
the second most frequent serotype and made up for 10.6% of
PNSP. All of these ﬁndings suggest that PCV7 vaccination may
not be the sole factor for the observed increase of serotype 19A
in areas where PCV7 was widely used, and that antimicrobial
abuse may also play a vital role in the serotype replacement
phenomenon.19 1 5;1  9(2):141–145
In conclusion, the current study examined the serotype
distribution and antimicrobial resistance of noninvasive
pneumococcal infections in Shanghai, China. Our data
demonstrated that the use of PCV7, PCV10 and PCV13 has
the potential to decrease the incidence of the pneumococcal
infections, similarly to what has been observed in developed
countries. Hence, long-term surveillance of S. pneumoniae is
required to monitor the dynamic changing of serotypes and
antimicrobial resistance, which would likely provide the basis
for choosing optimal vaccines for the prevention of pneu-
mococcal infections and developing new and more  effective
vaccines.
This study has several limitations. Firstly, all of the NIPD
strains were isolated from pediatric patients from one hospi-
tal in China. Additionally, this study only analyzed the NIPD
specimens, without inclusion of isolates from invasive pneu-
mococcal diseases. Therefore, a multicenter study including
isolates from more  pediatric hospitals should be conducted.
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